• Gretchen G Collins, Jill A Gadzinski, Garrett D Fitzgerald, Jordan Sheran, Sarah Wagner, Steven Edelstein, and Elizabeth R Mueller.
• Department of Obstetrics and Gynecology, Loyola University Chicago Stritch School of Medicine, Maywood, IL. Electronic address: gg.garbe@gmail.com.
• J Minim Invasive Gynecol. 2016 Jan 1; 23 (1): 40-5.

Study ObjectiveTo investigate the role of intraoperative atomized intraperitoneal ropivacaine (AIR) as an adjuvant to anesthetic agents at the time of minimally invasive pelvic surgery.DesignDouble-blind, randomized controlled trial.DesignClassificationRandomized controlled trial (Canadian Task Force classification I).SettingTertiary care teaching hospital.ParticipantsFifty-five patients who underwent laparoscopic and robotic gynecologic procedures.InterventionPatients received AIR or atomized intraperitoneal saline (AIS) (dose, 2 mg/kg) immediately after the initiation of pneumoperitoneum.Measurements And Main ResultsVisual analog scale (VAS) pain scores and narcotic use (in morphine equivalents) were collected and recorded at 2, 4, 8, and 12 hours postoperatively.ResultsFifty-five patients completed the study protocol and data collection, with 30 patients allocated to the AIS group and 25 patients allocated to the AIR group. Demographic and surgical variables did not vary between the groups, with the exception of median operative duration. Postoperative VAS scores at 2, 4, 8, and 12 postoperative hours were higher in the AIS group, but the difference failed to reach statistical significance. Narcotic use was also similar in the 2 groups.ConclusionThe use of intraperitoneal ropivacaine was not associated with a statistically significant difference in patients' postoperative VAS scores. Thus, in contrast to findings of similar studies performed in general surgery, AIR might not confer a benefit in women undergoing minimally invasive gynecologic procedures.Copyright © 2016 AAGL. Published by Elsevier Inc. All rights reserved.

26 keywords...

hide…